Dr. Konduri on Sequencing Challenges in ALK+ NSCLC | OncLive

Dr. Konduri on Sequencing Challenges in ALK+ NSCLC

September 8, 2020

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, site research leader, chair, Chest Site Tumor Committee, Texas Oncology-Baylor Charles A. Sammons Cancer Center, associate chair, Lung Cancer Research Committee, US Oncology Research, and chair, Lung Cancer Pathways Committee, The US Oncology Network, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer (NSCLC).

With an influx of available ALK-targeted therapies, sequencing remains an unmet need in this subgroup of patients with NSCLC, Konduri explains.

Future research efforts should focus on how certain sequencing strategies could potentially aid in overcoming resistance mechanisms, concludes Konduri.


x